Denali Therapeutics Inc. filings document regulatory, financial and governance disclosures for a biotechnology company developing blood-brain-barrier-crossing therapeutics. Recent 8-K reports record operating results, FDA approval and launch-related disclosures for AVLAYAH™, clinical pipeline updates, and material events tied to collaboration agreements and royalty funding arrangements.
Denali’s proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. Its event filings also describe capital-structure and financing obligations, Regulation FD disclosures, exhibit-based press releases, and formal updates on TransportVehicle-enabled programs across lysosomal storage and neurodegenerative disease indications.
Denali Therapeutics Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 3, 2026 at 10:00 a.m. Pacific Time. Holders of 158,675,498 shares of common stock outstanding as of April 9, 2026 may vote.
Stockholders will elect three Class III directors (Jennifer Cook, David Schenkein, M.D., and President and CEO Ryan Watts, Ph.D.), ratify Ernst & Young LLP as independent auditor for 2026, and approve, on an advisory basis, executive compensation. The board is composed of nine directors, eight of whom are independent, and recommends voting FOR all three proposals.
The proxy describes virtual participation and multiple voting methods, outlines board and committee structures, summarizes director independence, risk oversight, cybersecurity and environmental initiatives, and discloses 2024–2025 audit fees and stockholder procedures for future proposals and director nominations.
Denali Therapeutics Inc. Chief Medical Officer Peter Scott Chin filed an initial ownership report showing direct holdings of 170,612 shares of common stock, including 2,326 shares acquired under the Denali ESPP and 145,845 unvested RSUs. He also holds multiple fully vested or time-vesting stock options to buy common shares at exercise prices ranging from $20.17 to $80.03, with expirations extending through 2036. These positions reflect equity-based compensation typical for a senior executive and do not represent new market purchases or sales.
Denali Therapeutics reports that Takeda will terminate their collaboration agreement to co-develop and co-commercialize the investigational therapy DNL593 for GRN-related frontotemporal dementia. The decision is based on strategic considerations and not on efficacy or safety data.
The termination becomes effective 60 days after the April 3, 2026 notice, at which point all rights in the DNL593 program and its intellectual property will revert to Denali, and Denali will have no further financial obligations to Takeda. Denali plans to continue independent clinical development of DNL593 and expects results from an ongoing Phase 1/2 study by the end of 2026.
Denali Therapeutics Inc. reported that on March 27, 2026 it received $200.0 million in gross proceeds at the closing of its previously disclosed synthetic royalty funding agreement with Royalty Pharma. The closing occurred after the U.S. Food and Drug Administration granted accelerated approval to tividenofusp alfa on March 24, 2026.
Denali Therapeutics Inc: Amendment No. 6 to a Schedule 13G/A states that The Vanguard Group beneficially owns 0 shares of Denali common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries and business divisions to report separately.
Denali Therapeutics reported that the U.S. FDA granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), an enzyme replacement therapy for neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.
The drug is specifically engineered to cross the blood-brain barrier using Denali’s TransportVehicle platform and showed a 91% reduction in cerebrospinal fluid heparan sulfate by week 24 in a Phase 1/2 trial, with most treated patients reaching levels seen in individuals without Hunter syndrome. Continued approval may depend on confirmatory benefit in the ongoing Phase 2/3 COMPASS study, and the FDA granted Denali a Rare Pediatric Disease Priority Review Voucher in connection with the approval.
Denali Therapeutics outlines its strategy to use its proprietary Transport Vehicle (TV) platform to move large-molecule drugs across the blood–brain barrier and treat neurodegenerative and lysosomal storage diseases. The report emphasizes three pillars: Discover, Develop and Deliver, with specific three‑year “D3X3” goals.
Lead program tividenofusp alfa for Hunter syndrome has a biologics license application under priority review, with a PDUFA target action date of April 5, 2026, and is intended as the company’s first commercial launch. DNL126 for Sanfilippo syndrome type A, multiple Alzheimer’s programs (DNL628 and DNL921), Pompe candidate DNL952 and LRRK2 inhibitor BIIB122/DNL151 for Parkinson’s disease are progressing through clinical development under collaborations with Biogen, Takeda and Sanofi. The company reports 158,591,491 common shares outstanding as of February 20, 2026 and describes a rare‑disease–focused commercial build‑out intended to fund broader TV-platform expansion.
Denali Therapeutics reported a wider net loss of $128.5 million for the fourth quarter and $512.5 million for full-year 2025, compared with losses of $114.8 million and $422.8 million in 2024. Net loss per share was $0.73 for the quarter and $2.97 for the year.
Research and development expenses were $97.9 million in the quarter and $418.8 million for the year, while general and administrative costs rose to $39.5 million and $136.6 million, mainly to prepare for the potential launch of tividenofusp alfa for Hunter syndrome. Denali ended 2025 with $966.2 million in cash, cash equivalents and marketable securities, helped by a $275.0 million synthetic royalty funding deal with Royalty Pharma and approximately $200.0 million in net proceeds from a public offering.
The company highlighted launch readiness for tividenofusp alfa ahead of the April 5, 2026 PDUFA decision and encouraging biomarker data for DNL126 in Sanfilippo syndrome type A. Multiple additional programs advanced across Alzheimer’s disease, Pompe disease, frontotemporal dementia, Parkinson’s disease and ulcerative colitis, with several key clinical readouts expected in 2026.
Denali Therapeutics insider Carole Ho has filed a Rule 144 notice to sell 39,490 shares of common stock. The shares are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of 801,394.26.
The shares were acquired on 02/05/2026 by exercising stock options under a registered plan for cash. In the prior three months, Carole Ho sold 150,000 common shares on 02/03/2026 for gross proceeds of 3,324,060.00 and 150,000 common shares on 02/04/2026 for gross proceeds of 3,176,970.00.